A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

Stopped The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea.

Conditions

• Non-small Cell Lung Cancer
• Metastatic Colorectal Cancer
• Metastatic Breast Cancer
• Metastatic Kidney Cancer
• Cervical Cancer
• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Primary Peritoneal Cancer

Interventions

• DRUG: Zirabev

Sponsor

Pfizer